News ALZpath licenses Alzheimer’s diagnosis tech to Roche Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.
News Trial raises hopes for simple Alzheimer’s blood test Testing a person’s blood for a protein called phosphorylated tau could provide a means of large-scale screening for Alzheimer’s disease (AD), according to a new study.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
